Erick Vidjin′ Agnih Gbodossou

Erick Vidjin Agnih Gbodossou, a resident of Dakar-Etoile, SN, is an inventor and researcher in the field of antiviral compositions and methods. Gbodossou has been granted two patents for his innovative work in this area.

One of Gbodossou's recent patents is titled "Antiviral Compositions and Methods." This patent describes compositions and methods that utilize a MOMO30 protein derived from HIV. The MOMO30 protein exhibits various properties, including stability even after autoclaving, resistance to proteolytic cleavage, mannose-sensitive binding to HIV gp120, hemagglutinin and chitinase activity, and the ability to activate and stimulate T cell proliferation. This protein can be used to prevent or treat viral infections caused by HIV and other enveloped viruses.

In addition, Gbodossou has also patented a method for treating coronavirus infections. This patent, titled "Method of Treating Coronavirus Infections," describes a composition and method that involves using the same MOMO30 protein mentioned earlier. This protein has been shown to have multiple functions, such as binding to the coronavirus S protein, resistance to autoclaving and proteolytic cleavage, mannose-sensitive binding to coronavirus spike (S) protein, and the ability to prevent infection or alleviate symptoms in coronavirus-infected patients.

Gbodossou is affiliated with the Morehouse School of Medicine, where he conducts his research and contributes to the advancement of medical innovations.

One of Gbodossou's colleagues at the Morehouse School of Medicine is Michael D. Powell, who likely collaborates with Gbodossou on their shared research interests.

The work of inventors like Erick Vidjin Agnih Gbodossou plays a vital role in developing new strategies and tools to combat viral infections and improve public health.